Japan’s Regenerative Medicine Regulated by Two Pillars: Approved Cell Products and Registered Private Treatments, Emphasizing Safety and Quality

August 17, 2026

Stem Cell Clarity Japan

Overview

Japanese regenerative medicine is governed by two distinct legal frameworks: cell products approved by the Minister of Health, Labour and Welfare, and private treatments under a registration system where medical institutions submit plans to a certified committee before offering treatment. While this registration system reviews safety and process validity, it does not certify efficacy for specific diseases. This regulatory structure aims to promote clinical application and dissemination of regenerative medicine while prioritizing safety and quality assurance. Japan’s approach is recognized internationally as a model for rapidly delivering innovative therapies to patients.

In Depth

Key Findings

Japanese regulations for regenerative medicine are managed under two distinct legal frameworks: ‘approved cell products’ sanctioned by the Minister of Health, Labour and Welfare, and private treatments based on a ‘registration system’ requiring medical institutions to submit treatment plans to a certified committee prior to offering them. This clear distinction ensures rigorous safety and quality assurance in regenerative medicine, enabling patients to make treatment choices based on more transparent information.

Technical & Clinical Details

Japan’s Act on the Safety of Regenerative Medicine (ASRM) defines the classification of treatments and regulatory requirements as follows:

Approved Cell Products: These are regenerative medicine products developed by pharmaceutical companies, with proven efficacy and safety through clinical trials, and approved by the Minister of Health, Labour and Welfare. They undergo strict reviews and may be covered by public health insurance, similar to conventional pharmaceuticals. Manufacturing processes and quality control must adhere to Good Manufacturing Practice (GMP) standards, demanding extremely high quality.
Private Treatments under the Registration System: When medical institutions offer regenerative medicine treatments other than approved cell products, such as those using a patient’s own cells, they must submit their treatment plans in advance to an MHLW-certified committee (Regenerative Medicine Committee). This committee reviews the scientific and ethical validity and safety of the plan. It is crucial to note that this review confirms the safety of the treatment itself and the appropriateness of the process, but does not certify “efficacy for specific diseases.” The committee rigorously evaluates the treatment implementation plan, cell processing methods, risk management systems, and patient disclosure procedures.

This system allows for relatively rapid clinical application of new regenerative medicine while simultaneously ensuring patient protection. Furthermore, data from treated patients are tracked in a safety database, contributing to long-term evaluation of safety and efficacy.

Background & Context

The Act on the Safety of Regenerative Medicine, enforced in 2014, was introduced with the aim of quickly translating research findings from iPS cells and other areas into clinical applications. This law is unique compared to Western regulations, as it provides a strict framework for ensuring patient safety while promoting the provision of innovative regenerative medicine. Special expedited routes have been established for cell and gene therapies, which have characteristics different from conventional pharmaceuticals, enabling flexible and rapid evaluation and approval. However, this also demands high ethical standards, specialized knowledge, and transparent information disclosure from medical institutions. This legislative development is positioned as part of Japan’s national strategy to lead the world in regenerative medicine.

Strategic Significance & Outlook

Japan’s dual regulatory framework for regenerative medicine is expected to continue promoting both domestic and international innovation while strengthening patient protection. Approved cell products will become available to a broader range of patients based on established efficacy and safety, while treatments under the registration system will enable the early practical application of innovative approaches addressing specific clinical needs. However, for treatments under the registration system, further information provision and transparency improvements are needed to prevent misunderstandings about efficacy and ensure patients can make informed decisions. This system is expected to continue playing a crucial role in enhancing the quality of medical care in Japan and offering new hope to patients suffering from intractable diseases.

Source: https://iikamo-handa.jp/archives/49

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.